Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 17;63(2):272-280.
doi: 10.1093/jrr/rrab118.

Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis

Qingren Lin  1 , Ning Zhou  1 , Xiang Zhu  1 , Juan Lin  1 , Jun Fang  1 , Feiying Gu  1 , Xiaojiang Sun  1 , Yuezhen Wang  1
Affiliations

Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis

Qingren Lin et al. J Radiat Res. .

Abstract

The benefit of local ablative therapy (LAT) for oligo-recurrence has been investigated and integrated into the treatment framework. In recent decades, stereotactic body radiation therapy (SBRT) has been increasingly used to eliminate metastasis owing to its high rate of local control and low toxicity. This study aimed to investigate the outcomes of SBRT for patients with lung oligo-recurrence of non-small cell lung cancer (NSCLC) from our therapeutic center. Patients with lung oligo-recurrence of NSCLC treated with SBRT between December 2011 and October 2018 at Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) were reviewed. The characteristics, treatment-related outcomes, and toxicities of the patients were analyzed. Univariable and multivariable Cox regression were performed to identify the factors associated with survival. A total of 50 patients with lung oligo-recurrence of NSCLC were enrolled. The median follow-up period was 23.6 months. The 3-year local progression-free survival (LPFS), progression-free survival (PFS) and overall survival (OS) after SBRT were 80.2%, 21.9% and 45.3%, respectively. Patients in the subgroup with LAT to all residual diseases showed significantly improved OS and PFS. No treatment-related death occurred after SBRT. SBRT is a feasible option to treat patients with lung oligo-recurrence of NSCLC, with high rates of local control and low toxicity. LAT to all residual diseases was associated with better survival outcomes. Future prospective randomized clinical trials should evaluate SBRT strategies for such patients.

Keywords: lung metastases; non-small cell lung cancer (NSCLC); oligo-recurrence; stereotactic body radiotherapy (SBRT).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
LPFS (A), RPFS (B), DMPFS (C) and PFS (D) of patients after SBRT for lung oligo-recurrence of NSCLC.
Fig 2
Fig 2
Kaplan–Meier curves and estimated cumulative incidences of OS after SBRT for lung oligo-recurrence of NSCLC.
Fig. 3
Fig. 3
Kaplan–Meier plot of (A) PFS and (B) OS in all-LAT and partial-LAT subgroups.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90. - PubMed
    1. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010;40:107–11. - PMC - PubMed
    1. Collen C, Christian N, Schallier D et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 2014;25:1954–9. - PubMed
    1. Agolli L, Valeriani M, Nicosia L et al. Stereotactic ablative body radiotherapy (SABR) in pulmonary Oligometastatic/Oligorecurrent non-small cell lung cancer patients: a new therapeutic approach. Anticancer Res 2015;35:6239–45. - PubMed